Italia markets open in 53 minutes

ACIU Aug 2024 5.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,25000,0000 (0,00%)
In data: 11:13AM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,2500
Aperto0,3000
Denaro0,2000
Domanda0,2500
Prezzo d'esercizio5,00
Scadenza2024-08-16
Min-Max giorno0,2000 - 0,3000
Contratto - Min-MaxN/D
Volume285
Open Interest2,81k
  • GlobeNewswire

    AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023

    AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will present a corporate overview and participate in one-on-one investor meetings during the Jefferies 2023 CNS & Neuro Summit, taking place in-person in New York City on October 11-12, 2023. AC Immune’s cor

  • GlobeNewswire

    AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

    AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 Lausanne, Switzerland, September 05, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company will present a corporate overview and participate in one-on-one investor meetings during the H.C. Wainwright 25th Annual Global Investment Conference, taking place virtually and in-perso

  • GlobeNewswire

    AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

    AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update Received FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat Alzheimer’s disease (AD)Enrollment in ongoing Phase 1b/2 ABATE study of ACI-24.060 in AD and Down syndrome (DS) is on track and expanding to sites in USA following IND clearance, dosed first individual with DSNext interim safety and immunogenicity data from AD and DS cohorts in ABATE expected in H2 2023R